TY - JOUR T1 - Lymphatic Vessels in Regenerative Medicine and Tissue Engineering JF - Tissue Engineering Part B Y1 - 2016 AB - Once a DOI is available for this article, the final publication will be available from Mary Ann Liebert, Inc., publishers at http://dx.doi.org/10.1089/TEN.TEB.2016.0034. The postprint manuscript is available from here and for the next 30 days also from the publisher via this bit.ly shortcut: http://bit.ly/1VKjjMk. VL - 22 UR - http://online.liebertpub.com/doi/10.1089/ten.TEB.2016.0034 IS - 5 ER - TY - JOUR T1 - Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization JF - Cancer Cell Y1 - 2010 A1 - Tvorogov, Denis A1 - Anisimov, Andrey A1 - Zheng, Wei A1 - Leppänen, Veli-Matti A1 - Tammela, Tuomas A1 - Laurinavicius, Simonas A1 - Holnthoner, Wolfgang A1 - Heloterä, Hanna A1 - Holopainen, Tanja A1 - Jeltsch, Michael A1 - Kalkkinen, Nisse A1 - Lankinen, Hilkka A1 - Ojala, Päivi M A1 - Alitalo, Kari AB - Antibodies that block vascular endothelial growth factor (VEGF) have become an integral part of antiangiogenic tumor therapy, and antibodies targeting other VEGFs and receptors (VEGFRs) are in clinical trials. Typically receptor-blocking antibodies are targeted to the VEGFR ligand-binding site. Here we describe a monoclonal antibody that inhibits VEGFR-3 homodimer and VEGFR-3/VEGFR-2 heterodimer formation, signal transduction, as well as ligand-induced migration and sprouting of microvascular endothelial cells. Importantly, we show that combined use of antibodies blocking ligand binding and receptor dimerization improves VEGFR inhibition and results in stronger inhibition of endothelial sprouting and vascular network formation in vivo. These results suggest that receptor dimerization inhibitors could be used to enhance antiangiogenic activity of antibodies blocking ligand binding in tumor therapy. VL - 18 UR - http://view.ncbi.nlm.nih.gov/pubmed/21130043 IS - 6 JO - Cancer Cell ER -